CGRP Forum is made possible thanks to support from AbbVie, Lilly, Organon and Pfizer, all of whom have no influence or control of editorial content. More information is available here »

Positive data reported for eptinezumab in Sunrise trial New insights on treatment holidays with erenumab Dual CGRP ligand mAb and gepant therapy reduces headache severity CGRP-mAb switching yields migraine day reduction Lower switching rates with atogepant than CGRP mAbs EMBRACE shows erenumab reduces migraine severity Older patients benefit from CGRP mAbs too DELIVER shows long term QoL benefits with eptinezumab

Atogepant

Atogepant

Atogepant is an oral CGRP receptor antagonist (gepant) in development for the prevention of migraine. Results of a Phase 2b/3 study and the Phase 3 ADVANCE trial will form the basis of regulatory submissions for atogepant in migraine prevention in adults.

Download slideset »

« back to Slides

Educational Partners and Supporters

This program is funded in part via an independent educational grant from AbbVie.

Organon has provided sponsorship towards this independent resource. Organon has had no editorial input or control over content, nor opportunity to influence.

Financial support was provided as GMG Knowledge Gap Grant from Pfizer Inc, Pfizer have provided only financial support and had no input into the content provided.

Editorial PolicyCGRP Forum is an expert resource for clinicians and healthcare professionals working with migraine patients. All patients should discuss their medication with their healthcare professional. Unless otherwise indicated, opinions expressed in the CGRP Education and Research Forum are those of the contributors. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the CGRP Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.

© 2024 | Privacy Policy | Editorial Policy | Governance | Disclaimer Statement | Partnership & Outreach | Educational Partners and Supporters |